Paper30408564
Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation.
Raj K and 24 others. Biol Blood Marrow Transplant, 2019. Cited by 50 papers, by iCite.
Cite this record
ConductScience Library. Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation. Papers, record 30408564. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30408564
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation.
- PubMed
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Family | Major topic |
| Hematopoietic Stem Cell Transplantation | Major topic |
| Histocompatibility | Major topic |
| Primary Myelofibrosis | Major topic |
| Adult | |
| Aged | |
| Bone Marrow Transplantation | |
| Databases, Factual | |
| Europe | |
| Female | |
| Graft Survival | |
| Graft vs Host Disease | |
| Humans | |
| Male | |
| Middle Aged | |
| Peripheral Blood Stem Cell Transplantation | |
| Recurrence | |
| Retrospective Studies | |
| Societies, Medical | |
| Survival Analysis | |
| Transplantation Conditioning | |
| Transplantation, Homologous |
Source PubMed
Cited by28
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 50 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41537336 | Platelet recovery delay and survival in patients with myelofibrosis undergoing allogeneic hemopoietic stem cell transplantation. | Haematologica | 2026 | https://conductscience.org/library/papers/41537336 | PubMed |
| 40879525 | Impact of Donor Type on Outcomes After Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: A Study on Behalf of the Chronic Malignancies Working Party of the EBMT. | Am J Hematol | 2025 | https://conductscience.org/library/papers/40879525 | PubMed |
| 38916866 | Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study. | Blood Adv | 2024 | https://conductscience.org/library/papers/38916866 | PubMed |
| 38773281 | Anti-T-lymphocyte globulin improves GvHD-free and relapse-free survival in myelofibrosis after matched related or unrelated donor transplantation. | Bone Marrow Transplant | 2024 | https://conductscience.org/library/papers/38773281 | PubMed |
| 38378917 | Comparison of haploidentical transplantation and single cord blood transplantation for myelofibrosis. | Bone Marrow Transplant | 2024 | https://conductscience.org/library/papers/38378917 | PubMed |
| 38066916 | Are transplant indications changing for myelofibrosis? | Hematology Am Soc Hematol Educ Program | 2023 | https://conductscience.org/library/papers/38066916 | PubMed |
| 37637037 | Characterization of engraftment dynamics in myelofibrosis after allogeneic hematopoietic cell transplantation including novel conditioning schemes. | Front Oncol | 2023 | https://conductscience.org/library/papers/37637037 | PubMed |
| 37601853 | Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice. | EJHaem | 2023 | https://conductscience.org/library/papers/37601853 | PubMed |
| 36959692 | Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single Center | Balkan Med J | 2023 | https://conductscience.org/library/papers/36959692 | PubMed |
| 36861402 | Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis. | Haematologica | 2023 | https://conductscience.org/library/papers/36861402 | PubMed |
| 35455686 | The Use of Allogeneic Hematopoietic Stem Cell Transplantation in Primary Myelofibrosis. | J Pers Med | 2022 | https://conductscience.org/library/papers/35455686 | PubMed |
| 35419771 | Improving allogeneic stem cell transplantation in myelofibrosis. | Int J Hematol | 2022 | https://conductscience.org/library/papers/35419771 | PubMed |
| 35159362 | How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation. | Cells | 2022 | https://conductscience.org/library/papers/35159362 | PubMed |
| 35158092 | Post-Transplantation Cyclophosphamide-Based Graft- versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis. | Transplant Cell Ther | 2022 | https://conductscience.org/library/papers/35158092 | PubMed |
| 34911786 | Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape. | Cancer Res | 2022 | https://conductscience.org/library/papers/34911786 | PubMed |
| 34889421 | Novel therapies vs hematopoietic cell transplantation in myelofibrosis: who, when, how? | Hematology Am Soc Hematol Educ Program | 2021 | https://conductscience.org/library/papers/34889421 | PubMed |
| 34663912 | Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. | Leukemia | 2022 | https://conductscience.org/library/papers/34663912 | PubMed |
| 34536293 | 2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management. | Am J Hematol | 2021 | https://conductscience.org/library/papers/34536293 | PubMed |
| 34052505 | Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis-A Systematic Review and Meta-Analysis. | Transplant Cell Ther | 2021 | https://conductscience.org/library/papers/34052505 | PubMed |
| 34017327 | Allogeneic Hemopoietic Stem Cell Transplantation for Myelofibrosis: 2021. | Front Immunol | 2021 | https://conductscience.org/library/papers/34017327 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD34 | 947 | PubTator's text mining | https://conductscience.org/library/genes/947 | NCBI Gene |
| HLA-A | 3105 | PubTator's text mining | https://conductscience.org/library/genes/3105 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30408564
GET https://conductscience.org/api/papers/v1/30408564/authors?page=2